US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Alumis Inc.

4.28

-0.0300-0.70%

Post-market: 4.280.00000.00%19:50 EDT

Volume:181.49K

Turnover:774.50K

Market Cap:232.86M

PE:-0.41

High:4.49

Open:4.29

Low:4.16

Close:4.31

Loading ...

Overview Company News Filings

Owning 32% shares,hedge funds owners seem interested in Alumis Inc. (NASDAQ:ALMS),

Simply Wall St.

Alumis Price Target Maintained With a $26.00/Share by HC Wainwright & Co.

BRIEF-Alumis Announces Positive Phase 1 Data For Cns Penetrant Tyk2 Inhibitor, A-005

Alumis Inc: Data Support Advancement to Phase 2 Clinical Trial in Multiple Sclerosis, Anticipated in 2H 2025

THOMSON REUTERS

Alumis Inc: Maximal Tyk2 Inhibition Achieved With Favorable Pharmacokinetic Profile in CNS and Periphery

THOMSON REUTERS

Alumis Announces Positive Phase 1 Data for CNS Penetrant Tyk2 Inhibitor, a-005

THOMSON REUTERS

Alumis Inc: a-005 Was Well Tolerated and Demonstrated Ability to Cross Blood-Brain Barrier

THOMSON REUTERS

Alumis Announces Positive Phase 1 Data for CNS Penetrant TYK2 Inhibitor, A-005

Buy Rating for Alumis Inc. Driven by Promising ESK-001 Clinical Results and Reduced Competition

Alumis Inc.: Promising Clinical Advancements and Strategic Positioning Drive Buy Rating

Alumis Inc. Reports Q3 2024 Financial Results and Advances Clinical Programs

Alumis Presents Data Highlighting ESK-001’s Potential as a High-efficacy Oral Treatment for Systemic Lupus Erythematosus (SLE) at ACR Convergence 2024

Alumis Is Maintained at Buy by HC Wainwright & Co.

Alumis price target lowered to $26 from $30 at H.C. Wainwright

Alumis Q3 EPS $(1.73) Beats $(4.50) Estimate

Press Release: Alumis Reports Third Quarter 2024 Financial Results and Highlights Recent Achievements

Alumis to Participate in Guggenheim's Inaugural Healthcare Innovation Conference

Baird Initiates Alumis at Outperform With $25 Price Target

MT Newswires Live

Alumis Initiated at Outperform by Baird

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/stock/ALMS/news?page=5"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"ALMS","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ALMS\",,,,,undefined,":{"symbol":"ALMS","market":"US","secType":"STK","nameCN":"Alumis Inc.","latestPrice":4.28,"timestamp":1745611200000,"preClose":4.31,"halted":0,"volume":181491,"hourTrading":{"tag":"盘后","latestPrice":4.28,"preClose":4.28,"latestTime":"19:50 EDT","volume":1161,"amount":4970.348,"timestamp":1745625044435},"delay":0,"floatShares":4764683,"shares":54407327,"eps":-10.381567,"marketStatus":"Market Closed","change":-0.03,"latestTime":"04-25 16:00:00 EDT","open":4.29,"high":4.4884,"low":4.16,"amount":774495.7823460001,"amplitude":0.076195,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-10.381567,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1745827200000},"marketStatusCode":7,"adr":0,"listingDate":1719547200000,"exchange":"NASDAQ","adjPreClose":4.31,"preHourTrading":{"tag":"盘前","latestPrice":4.36,"preClose":4.31,"latestTime":"09:29 EDT","volume":122,"amount":540.441944,"timestamp":1745587799998},"postHourTrading":{"tag":"盘后","latestPrice":4.28,"preClose":4.28,"latestTime":"19:50 EDT","volume":1161,"amount":4970.348,"timestamp":1745625044435},"volumeRatio":0.5495577276056506,"impliedVol":0.8308,"impliedVolPercentile":0.25},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ALMS\",,,,,undefined,":{"symbol":"ALMS","floatShares":4764683,"roa":"-87.31%","roe":"-198.66%","lyrEps":-10.381567,"volumeRatio":0.5495577276056506,"shares":54407327,"dividePrice":0,"high":4.4884,"amplitude":0.076195,"preClose":4.31,"low":4.16,"week52Low":3.18,"pbRate":"0.90","week52High":13.53,"institutionHeld":0,"latestPrice":4.28,"eps":-10.381567,"divideRate":0,"volume":181491,"delay":0,"ttmEps":-10.381567,"open":4.29,"prevYearClose":7.86,"prevWeekClose":5,"prevMonthClose":6.14,"prevQuarterClose":6.14,"fiveDayClose":5,"twentyDayClose":4.7,"sixtyDayClose":6.53},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"ALMS\",pageSize:20,pageCount:5,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2494231781","title":"Owning 32% shares,hedge funds owners seem interested in Alumis Inc. (NASDAQ:ALMS),","url":"https://stock-news.laohu8.com/highlight/detail?id=2494231781","media":"Simply Wall St.","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2494231781?lang=en_us&edition=fundamental","pubTime":"2024-12-28 21:27","pubTimestamp":1735392472,"startTime":"0","endTime":"0","summary":"Significantly high institutional ownership implies Alumis' stock price is sensitive to their trading actions. A total of 4 investors have a majority stake in the company with 53% ownership. Using data from analyst forecasts alongside ownership research, one can better assess the future performance of a company. Every investor in Alumis Inc.  should be aware of the most powerful shareholder groups. With 32% stake, hedge funds possess the maximum shares in the company. That is, the group stands to benefit the most if the stock rises .In the chart below, we zoom in on the different ownership groups of Alumis.NasdaqGS:ALMS Earnings and Revenue Growth December 28th 2024. Researching institutional ownership is a good way to gauge and filter a stock's expected performance. The same can be achieved by studying analyst sentiments. There are a reasonable number of analysts covering the stock, so it might be useful to find out their aggregate view on","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/owning-32-shares-hedge-funds-132752215.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU2210150020.SGD","USAW.SI","USJW.SI","BK4585","TSYW.SI",".IXIC","SQQQ","QID","ALMS","QLD","NDAQ","IE00BGHQF748.EUR","IE00B64PRP62.GBP","IE00BKPKM429.USD","BK4007","LU2095319765.USD","BK4112","PSQ","LU2210149790.SGD","MNQmain","TQQQ","IE00B3QW5Z07.USD","NVIW.SI","NQmain","BK4588"],"gpt_icon":1},{"id":"2492938410","title":"Alumis Price Target Maintained With a $26.00/Share by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2492938410","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2492938410?lang=en_us&edition=fundamental","pubTime":"2024-12-20 20:50","pubTimestamp":1734699000,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/ALMS/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  December 20, 2024 07:50 ET (12:50 GMT)","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ALMS"],"gpt_icon":0},{"id":"2492120452","title":"BRIEF-Alumis Announces Positive Phase 1 Data For Cns Penetrant Tyk2 Inhibitor, A-005","url":"https://stock-news.laohu8.com/highlight/detail?id=2492120452","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2492120452?lang=en_us&edition=fundamental","pubTime":"2024-12-19 21:23","pubTimestamp":1734614635,"startTime":"0","endTime":"0","summary":"BRIEF-Alumis Announces Positive Phase 1 Data For Cns Penetrant Tyk2 Inhibitor, A-005Dec 19 (Reuters) - Alumis Inc ALMS.O:ALUMIS ANNOUNCES POSITIVE PHASE 1 DATA FOR CNS PENETRANT TYK2 INHIBITOR, A-005A","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241219:nTUABZ385M:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ALMS","BK4007"],"gpt_icon":0},{"id":"2492712798","title":"Alumis Inc: Data Support Advancement to Phase 2 Clinical Trial in Multiple Sclerosis, Anticipated in 2H 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2492712798","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2492712798?lang=en_us&edition=fundamental","pubTime":"2024-12-19 21:00","pubTimestamp":1734613200,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241219:nTUABZ385M:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ALMS","BK4007"],"gpt_icon":0},{"id":"2492512749","title":"Alumis Inc: Maximal Tyk2 Inhibition Achieved With Favorable Pharmacokinetic Profile in CNS and Periphery","url":"https://stock-news.laohu8.com/highlight/detail?id=2492512749","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2492512749?lang=en_us&edition=fundamental","pubTime":"2024-12-19 21:00","pubTimestamp":1734613200,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241219:nTUABZ385M:4","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ALMS","BK4007"],"gpt_icon":0},{"id":"2492276211","title":"Alumis Announces Positive Phase 1 Data for CNS Penetrant Tyk2 Inhibitor, a-005","url":"https://stock-news.laohu8.com/highlight/detail?id=2492276211","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2492276211?lang=en_us&edition=fundamental","pubTime":"2024-12-19 21:00","pubTimestamp":1734613200,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241219:nTUABZ385M:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","ALMS"],"gpt_icon":0},{"id":"2492112769","title":"Alumis Inc: a-005 Was Well Tolerated and Demonstrated Ability to Cross Blood-Brain Barrier","url":"https://stock-news.laohu8.com/highlight/detail?id=2492112769","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2492112769?lang=en_us&edition=fundamental","pubTime":"2024-12-19 21:00","pubTimestamp":1734613200,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241219:nTUABZ385M:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ALMS","BK4007"],"gpt_icon":0},{"id":"2492312729","title":"Alumis Announces Positive Phase 1 Data for CNS Penetrant TYK2 Inhibitor, A-005","url":"https://stock-news.laohu8.com/highlight/detail?id=2492312729","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2492312729?lang=en_us&edition=fundamental","pubTime":"2024-12-19 21:00","pubTimestamp":1734613200,"startTime":"0","endTime":"0","summary":"– A-005 was well tolerated and demonstrated ability to cross blood-brain barrier – – Maximal TYK2 inhibition achieved with favorable pharmacokinetic profile in CNS and periphery – – Data support advan","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2024/12/19/2999795/0/en/Alumis-Announces-Positive-Phase-1-Data-for-CNS-Penetrant-TYK2-Inhibitor-A-005.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1548497426.USD","LU2089284900.SGD","LU1169590202.USD","LU0267386448.USD","LU1169589451.USD","LU1668664300.SGD","LU2089283258.USD","LU0912757837.SGD","ALMS","LU0098860793.USD","LU1732800096.USD","LU1162221912.USD","LU0971096721.USD","LU0106831901.USD","LU1732799900.SGD","BK4127","LU1363072403.SGD","LU0314104364.USD","LU0320765646.SGD","BK4023","PK","LU2028103732.USD","IE00BKVL7J92.USD","LU0225283273.USD","BK4007","BK4504","LU2023251221.USD","LU2111349929.HKD","LU1989772923.USD","LU0158827781.USD","PD","LU1989772840.SGD","BK4516","LU2271345857.HKD","BK4534","IE00BZ1G4Q59.USD","CNS","LU0106261372.USD","BK4218","LU0158827948.USD","LU0795875169.SGD","LU1720051108.HKD","LU1074936037.SGD","LU2357305700.SGD","BK4181","BK4581","BK4585","BK4588","LU0795875086.SGD","CSF"],"gpt_icon":0},{"id":"2485243974","title":"Buy Rating for Alumis Inc. Driven by Promising ESK-001 Clinical Results and Reduced Competition","url":"https://stock-news.laohu8.com/highlight/detail?id=2485243974","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2485243974?lang=en_us&edition=fundamental","pubTime":"2024-11-21 14:18","pubTimestamp":1732169893,"startTime":"0","endTime":"0","summary":"Leerink Partners analyst Thomas Smith has maintained their bullish stance on ALMS stock, giving a Buy rating on November 15. Thomas Smith’s rating ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/buy-rating-for-alumis-inc-driven-by-promising-esk-001-clinical-results-and-reduced-competition?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/buy-rating-for-alumis-inc-driven-by-promising-esk-001-clinical-results-and-reduced-competition?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ALMS"],"gpt_icon":0},{"id":"2484627829","title":"Alumis Inc.: Promising Clinical Advancements and Strategic Positioning Drive Buy Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2484627829","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2484627829?lang=en_us&edition=fundamental","pubTime":"2024-11-19 14:45","pubTimestamp":1731998739,"startTime":"0","endTime":"0","summary":"Brian Skorney, an analyst from Robert W. Baird, maintained the Buy rating on Alumis Inc. (ALMS – Research Report). The associated price target rema...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/alumis-inc-promising-clinical-advancements-and-strategic-positioning-drive-buy-rating?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/alumis-inc-promising-clinical-advancements-and-strategic-positioning-drive-buy-rating?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ALMS"],"gpt_icon":0},{"id":"2483687305","title":"Alumis Inc. Reports Q3 2024 Financial Results and Advances Clinical Programs","url":"https://stock-news.laohu8.com/highlight/detail?id=2483687305","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483687305?lang=en_us&edition=fundamental","pubTime":"2024-11-16 12:02","pubTimestamp":1731729755,"startTime":"0","endTime":"0","summary":"Alumis Inc. ( ($ALMS) ) has released its Q3 earnings. Here is a breakdown of the information Alumis Inc. presented to its investors. Alumis Inc., a...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/alumis-inc-reports-q3-2024-financial-results-and-advances-clinical-programs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/alumis-inc-reports-q3-2024-financial-results-and-advances-clinical-programs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ALMS","BK4007"],"gpt_icon":0},{"id":"2483258337","title":"Alumis Presents Data Highlighting ESK-001’s Potential as a High-efficacy Oral Treatment for Systemic Lupus Erythematosus (SLE) at ACR Convergence 2024","url":"https://stock-news.laohu8.com/highlight/detail?id=2483258337","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483258337?lang=en_us&edition=fundamental","pubTime":"2024-11-15 05:05","pubTimestamp":1731618300,"startTime":"0","endTime":"0","summary":"SOUTH SAN FRANCISCO, Calif., Nov.  14, 2024  (GLOBE NEWSWIRE) -- Alumis Inc. (Nasdaq: ALMS), a clinical stage biopharmaceutical company developing oral therapies using a precision approach to optimize","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2024/11/14/2981606/0/en/Alumis-Presents-Data-Highlighting-ESK-001-s-Potential-as-a-High-efficacy-Oral-Treatment-for-Systemic-Lupus-Erythematosus-SLE-at-ACR-Convergence-2024.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","BK4077","ACR","ALMS","BK4110","SLE"],"gpt_icon":0},{"id":"2483131878","title":"Alumis Is Maintained at Buy by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2483131878","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483131878?lang=en_us&edition=fundamental","pubTime":"2024-11-14 19:24","pubTimestamp":1731583440,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/ALMS/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  November 14, 2024 06:24 ET (11:24 GMT)","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ALMS"],"gpt_icon":0},{"id":"2483878597","title":"Alumis price target lowered to $26 from $30 at H.C. Wainwright","url":"https://stock-news.laohu8.com/highlight/detail?id=2483878597","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483878597?lang=en_us&edition=fundamental","pubTime":"2024-11-14 19:15","pubTimestamp":1731582927,"startTime":"0","endTime":"0","summary":"H.C. Wainwright lowered the firm’s price target on Alumis (ALMS) to $26 from $30 and keeps a Buy rating on the shares following the Q3 report. Publ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/alumis-price-target-lowered-to-26-from-30-at-h-c-wainwright?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/alumis-price-target-lowered-to-26-from-30-at-h-c-wainwright?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ALMS"],"gpt_icon":0},{"id":"2483863203","title":"Alumis Q3 EPS $(1.73) Beats $(4.50) Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2483863203","media":"Benzinga","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483863203?lang=en_us&edition=fundamental","pubTime":"2024-11-14 05:34","pubTimestamp":1731533690,"startTime":"0","endTime":"0","summary":"Alumis (NASDAQ:ALMS) reported quarterly losses of $(1.73) per share which beat the analyst consensus estimate of $(4.50) by 61.56 percent. This is a 91.24 percent increase over losses of $(19.76) per share from the same","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/24/11/41955982/alumis-q3-eps-1-73-beats-4-50-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":"Alumis Q3 EPS $(1.73) Beats $(4.50) Estimate","news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ALMS"],"gpt_icon":0},{"id":"2483141868","title":"Press Release: Alumis Reports Third Quarter 2024 Financial Results and Highlights Recent Achievements","url":"https://stock-news.laohu8.com/highlight/detail?id=2483141868","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483141868?lang=en_us&edition=fundamental","pubTime":"2024-11-14 05:05","pubTimestamp":1731531900,"startTime":"0","endTime":"0","summary":"-- Presented data at EADV supporting potential of ESK-001 as differentiated oral treatment in immune-mediated diseases through maximal TYK2 inhibition --. -- Continued to advance three clinical programs, including global Phase 3 ONWARD clinical trials for ESK-001 in moderate-to-severe plaque psoriasis, Phase 2b clinical trial for ESK-001 in systemic lupus erythematosus  and Phase 1 clinical study for A-005 being developed for neuroinflammatory and neurodegenerative diseases --. SOUTH SAN FRANCISCO, Calif., Nov. 13, 2024  -- Alumis Inc. , a clinical-stage biopharmaceutical company developing oral therapies using a precision approach to optimize clinical outcomes and significantly improve the lives of patients with immune-mediated diseases, today reported financial results for the third quarter ended September 30, 2024, and highlighted recent achievements and upcoming milestones.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0106831901.USD","BK4504","LU0314104364.USD","LU0971096721.USD","LU1720051017.SGD","LU1668664300.SGD","BK4135","LU1989772840.SGD","LU2357305700.SGD","IE00BKVL7J92.USD","BK4077","BK4585","LU1989772923.USD","LU1548497426.USD","LU1363072403.SGD","BK4581","ACR","IE00BZ1G4Q59.USD","BK4110","BK4534","BK4588","BK4127","ALMS","BK4007","CNS","LU0225283273.USD","LU0267386448.USD","LU0320765646.SGD","BK4516","LU1074936037.SGD","LU0006306889.USD","LU1720051108.HKD","LU1162221912.USD","LU0106261372.USD","SLE","LU0098860793.USD"],"gpt_icon":0},{"id":"2480300355","title":"Alumis to Participate in Guggenheim's Inaugural Healthcare Innovation Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2480300355","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2480300355?lang=en_us&edition=fundamental","pubTime":"2024-11-04 21:00","pubTimestamp":1730725200,"startTime":"0","endTime":"0","summary":"SOUTH SAN FRANCISCO, Calif., Nov. 04, 2024  -- Alumis Inc. , a clinical-stage biopharmaceutical company developing oral therapies using a precision approach to optimize clinical outcomes and significantly improve the lives of patients with immune-mediated diseases, today announced that Martin Babler, President and Chief Executive Officer of Alumis, will participate in a fireside chat at Guggenheim’s Inaugural Healthcare Innovation Conference on Tuesday, November 12, 2024 at 2:00 pm ET in Boston, MA.A live webcast will be available on the Alumis website in the \"Investors\" section under the “Events” page. A replay of the conference webcast will be archived on the company's website for 90 days.Forward Looking StatementsThis press release may contain forward-looking statements, including statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These include, without limitation, statements regarding Alumis’ participation at upcoming con","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/2NYpvYmuqK3WlAh7C3b9IQ--~B/aD0zOTt3PTE1MDthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/globenewswire.com/6eb34a25d74ca457b5b279aeaabcd69c","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/2NYpvYmuqK3WlAh7C3b9IQ--~B/aD0zOTt3PTE1MDthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/globenewswire.com/6eb34a25d74ca457b5b279aeaabcd69c"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/alumis-participate-guggenheims-inaugural-healthcare-130000488.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["HCSG","ALMS","BK4007","BK4137"],"gpt_icon":0},{"id":"2479089050","title":"Baird Initiates Alumis at Outperform With $25 Price Target","url":"https://stock-news.laohu8.com/highlight/detail?id=2479089050","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2479089050?lang=en_us&edition=fundamental","pubTime":"2024-10-31 20:41","pubTimestamp":1730378492,"startTime":"0","endTime":"0","summary":"Baird Initiates Alumis at Outperform With $25 Price Target","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["ALMS"],"gpt_icon":0},{"id":"2479834703","title":"Alumis Initiated at Outperform by Baird","url":"https://stock-news.laohu8.com/highlight/detail?id=2479834703","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2479834703?lang=en_us&edition=fundamental","pubTime":"2024-10-31 18:08","pubTimestamp":1730369280,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/ALMS/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  October 31, 2024 06:08 ET (10:08 GMT)","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ALMS"],"gpt_icon":0}],"pageSize":20,"totalPage":5,"pageCount":5,"totalSize":99,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/ALMS\",params:#limit:5,,,undefined,":[{"market":"US","date":"2025-03-19","symbol":"ALMS","fiscalQuarterEnding":"2024/12","expectedEps":-1.39,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1742356800000,"reportTimeType":"post","actualEps":null},{"market":"US","date":"2024-11-13","symbol":"ALMS","fiscalQuarterEnding":"2024/09","expectedEps":-1.64,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1731474000000,"reportTimeType":"post","actualEps":-1.73}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"ALMS\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"ALMS\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.6,"buy":0.4,"hold":0,"sell":0,"strongSell":0,"meanLabel":"STRONG BUY","meanPercent":0.6,"analysts":5,"updateTime":1738296000000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/ALMS\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"ALMS","date":"2025-04-25","current":-0.796972,"percent":0.979167,"low":-5.220865,"twenty":-3.46104,"median":-2.0029,"eighty":-1.164826,"high":-0.660137,"avg":-2.35631,"sd":1.070192,"marketCap":234495579},"quantilePoints":[{"date":"2024-06-28","current":-5.220865,"twenty":-5.220865,"median":-5.220865,"eighty":-5.220865,"marketCap":881360393},{"date":"2024-07-05","current":-3.577828,"twenty":-4.31182,"median":-3.851156,"eighty":-3.577828,"marketCap":603991092},{"date":"2024-07-12","current":-3.798947,"twenty":-4.001025,"median":-3.825051,"eighty":-3.577828,"marketCap":641319297},{"date":"2024-07-15","current":-3.405847,"twenty":-3.980142,"median":-3.798947,"eighty":-3.577828,"marketCap":574958044},{"date":"2024-08-02","current":-4.08515,"twenty":-4.063676,"median":-3.825051,"eighty":-3.577828,"marketCap":689634611},{"date":"2024-08-09","current":-3.930629,"twenty":-4.063676,"median":-3.914533,"eighty":-3.58397,"marketCap":663549141},{"date":"2024-08-16","current":-3.699952,"twenty":-4.025518,"median":-3.855481,"eighty":-3.617622,"marketCap":699416662},{"date":"2024-08-23","current":-3.709695,"twenty":-3.973459,"median":-3.817957,"eighty":-3.659922,"marketCap":701258562},{"date":"2024-08-30","current":-3.67516,"twenty":-3.943506,"median":-3.741353,"eighty":-3.65762,"marketCap":694730166},{"date":"2024-09-06","current":-3.390241,"twenty":-3.930629,"median":-3.739914,"eighty":-3.608539,"marketCap":640870897},{"date":"2024-09-13","current":-3.240587,"twenty":-3.915649,"median":-3.699952,"eighty":-3.511116,"marketCap":612581180},{"date":"2024-09-20","current":-3.272245,"twenty":-3.914533,"median":-3.679477,"eighty":-3.395997,"marketCap":618565543},{"date":"2024-09-27","current":-3.444923,"twenty":-3.859807,"median":-3.655014,"eighty":-3.33556,"marketCap":651207524},{"date":"2024-10-04","current":-2.886598,"twenty":-3.851156,"median":-3.617387,"eighty":-3.295269,"marketCap":545665119},{"date":"2024-10-11","current":-2.961425,"twenty":-3.850149,"median":-3.577828,"eighty":-3.211808,"marketCap":559809977},{"date":"2024-10-18","current":-3.200296,"twenty":-3.817957,"median":-3.47802,"eighty":-3.18015,"marketCap":604964718},{"date":"2024-10-25","current":-3.444923,"twenty":-3.798947,"median":-3.465068,"eighty":-3.200296,"marketCap":651207524},{"date":"2024-10-31","current":-3.231953,"twenty":-3.752872,"median":-3.462191,"eighty":-3.209506,"marketCap":610949081},{"date":"2024-11-08","current":-3.367218,"twenty":-3.741353,"median":-3.447801,"eighty":-3.218715,"marketCap":636518633},{"date":"2024-11-15","current":-2.144174,"twenty":-3.741353,"median":-3.444923,"eighty":-3.209506,"marketCap":511972947},{"date":"2024-11-22","current":-2.15101,"twenty":-3.739051,"median":-3.433411,"eighty":-3.073089,"marketCap":513605166},{"date":"2024-11-29","current":-2.109995,"twenty":-3.736748,"median":-3.419021,"eighty":-3.008623,"marketCap":503811848},{"date":"2024-12-06","current":-1.964163,"twenty":-3.720056,"median":-3.405847,"eighty":-2.970059,"marketCap":468991158},{"date":"2024-12-13","current":-1.989228,"twenty":-3.703849,"median":-3.378729,"eighty":-2.667081,"marketCap":474975964},{"date":"2024-12-20","current":-1.966442,"twenty":-3.691984,"median":-3.312536,"eighty":-2.153744,"marketCap":469535232},{"date":"2024-12-27","current":-1.916313,"twenty":-3.685521,"median":-3.301025,"eighty":-2.142807,"marketCap":457565620},{"date":"2025-01-03","current":-1.873019,"twenty":-3.682067,"median":-3.286635,"eighty":-2.0626,"marketCap":447228227},{"date":"2025-01-10","current":-1.752253,"twenty":-3.67516,"median":-3.266489,"eighty":-2.0029,"marketCap":418392344},{"date":"2025-01-17","current":-1.775039,"twenty":-3.672282,"median":-3.247782,"eighty":-1.966442,"marketCap":423833077},{"date":"2025-01-24","current":-1.497048,"twenty":-3.658468,"median":-3.227637,"eighty":-1.954138,"marketCap":357456138},{"date":"2025-01-31","current":-1.531227,"twenty":-3.654166,"median":-3.211808,"eighty":-1.919959,"marketCap":365617237},{"date":"2025-02-07","current":-1.501605,"twenty":-3.631778,"median":-3.162882,"eighty":-1.882133,"marketCap":358544284},{"date":"2025-02-14","current":-1.162092,"twenty":-3.62163,"median":-3.070787,"eighty":-1.832004,"marketCap":277477367},{"date":"2025-02-21","current":-1.168928,"twenty":-3.613315,"median":-3.018984,"eighty":-1.784609,"marketCap":279109587},{"date":"2025-02-28","current":-1.064112,"twenty":-3.590112,"median":-2.978693,"eighty":-1.743594,"marketCap":254082217},{"date":"2025-03-07","current":-1.162092,"twenty":-3.577828,"median":-2.970059,"eighty":-1.696654,"marketCap":277477367},{"date":"2025-03-14","current":-1.045883,"twenty":-3.561975,"median":-2.844868,"eighty":-1.612801,"marketCap":249729630},{"date":"2025-03-21","current":-0.660137,"twenty":-3.530406,"median":-2.358363,"eighty":-1.527581,"marketCap":194234157},{"date":"2025-03-28","current":-0.869088,"twenty":-3.513232,"median":-2.153288,"eighty":-1.493402,"marketCap":255714436},{"date":"2025-04-04","current":-1.579152,"twenty":-3.504209,"median":-2.144174,"eighty":-1.320049,"marketCap":464638572},{"date":"2025-04-11","current":-1.262952,"twenty":-3.478882,"median":-2.109995,"eighty":-1.320049,"marketCap":371602043},{"date":"2025-04-17","current":-0.937506,"twenty":-3.463917,"median":-2.033661,"eighty":-1.195689,"marketCap":275845147},{"date":"2025-04-25","current":-0.796972,"twenty":-3.46104,"median":-2.0029,"eighty":-1.164826,"marketCap":234495579}],"updateTime":1745684309471}}}